USCOM LIMITED — Capital/Financing Update 2017

Dec 17, 2017

ASX MEDIA RELEASE

==> picture [53 x 64] intentionally omitted <==

International Value Investor Takes Strategic Stake in Uscom

• 10% cornerstone placement to Mr Steven Meng

• 13 million new shares to be issued at $0.135 per share, raising $1.755M

• Brings Uscom outstanding access to China sales and distribution

SYDNEY, Australia, Monday 18[th] December 2017: Uscom Limited (ASX code: UCM) (the Company or Uscom ) has secured a strategic investment from Mr Steven Meng, a private investor, and senior pharma executive for $1.755M in a placement of new shares.

Mr Meng is an experienced private and international value investor with investments across multiple sectors and countries, and has qualifications in economics, engineering management and business administration. Mr Meng has 10 years experience as a government departmental head (1987 to 1997), and 20 years experience in China pharma and medical devices, and remains the executive manager of a major Chinese Pharma, in which he was Executive Director from 2006 to 2017.

Mr Meng will bring both his international corporate and management skills to Uscom, including his excellent distribution contacts in China. Mr Meng has previously overseen a network of over 3,000 distributors with channels into over 10,000 Chinese hospitals across the 31 Chinese provinces, and access to his distribution network will enhance Uscom’s drive into China as seven new products are brought to market once CFDA is received during 2018. Uscom currently has approximately 50 distributors worldwide.

Uscom will issue 13 million new shares at $0.135 per share to Mr Meng, giving him a 10.3% initial stake in the company, at a 10% discount to the last closing price of $0.15. Uscom will use the funds raised in the placement to manufacture devices to fill outstanding orders and to build stock of the new BP+, complete global regulatory for all devices, and add clinical support and sales staff.

Mr Steven Meng said: “Uscom is an outstanding medical device company with a strong culture of product innovation, and I am looking forward to assisting it with growth in China. With the release of the new BP+ and SpiroSonic devices in 2018, distribution channels in China will become vital. Heart failure, hypertension, asthma and COPD are increasingly important diseases in China and success for Uscom is now dependent on the number and strength of distribution channels to deliver its products into China. I hope to grow these and help set the company on the path to strong growth in China.”

Executive Chairman of Uscom, Associate Professor Rob Phillips said: “Uscom is increasingly being recognised in the global medical devices domain, as this investment demonstrates. China is the driver of the world economy, and Mr Meng’s unique experience in Chinese channel management and corporate strategy are a perfect fit for Uscom as we ramp up our expanded sales and marketing activities in China. His long-term investment also supports the expansion of the company as it enters its next rapid growth phase. Preparing channels for the delivery of our seven new consumer products into China is a priority for us, and Mr Meng’s massive distribution network, contacts, and experience will significantly boost our strategic operations in China, and we welcome him to our register.”

The capital raising was facilitated by Sinonew Capital Advisory of Beijing.

The $1.755 constitutes part of the current capital raise which will close at end of business today (18[th] December 2017) with the full results released to market tomorrow following resumption of trading.

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au

==> picture [53 x 64] intentionally omitted <==

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) : An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A : A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ : A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary BP+ Reporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers : High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote telemonitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary SpiroReporter , an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney NSW 2000 Australia T: +612 9247 4144 E: info@uscom.com.au W: www.uscom.com.au